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In complex biological systems, small molecules often
mediate microbe-microbe and microbe-host inter-
actions. Using a systematic approach, we identi-
fied 3,118 small-molecule biosynthetic gene clusters
(BGCs) in genomes of human-associated bacteria
and studied their representation in 752metagenomic
samples from the NIH Human Microbiome Project.
Remarkably, we discovered that BGCs for a class
of antibiotics in clinical trials, thiopeptides, arewidely
distributed in genomes and metagenomes of the
human microbiota. We purified and solved the struc-
ture of a thiopeptide antibiotic, lactocillin, from
a prominent member of the vaginal microbiota. We
demonstrate that lactocillin has potent antibacterial
activity against a range of Gram-positive vaginal
pathogens, and we show that lactocillin and other
thiopeptide BGCs are expressed in vivo by analyzing
human metatranscriptomic sequencing data. Our
findings illustrate the widespread distribution of
small-molecule-encoding BGCs in the human micro-
biome, and they demonstrate the bacterial produc-
tion of drug-like molecules in humans.
INTRODUCTION
The human microbiome is composed of hundreds of bacterial
species and thousands of strains, and its composition differs
from person to person and between different body sites of the
same individual (Human Microbiome Project Consortium,
2012b). During the last decade, tremendous efforts have been
made to sequence isolates of the human microbiota and meta-
genomic samples from various body sites (Human Microbiome
Project Consortium, 2012a, 2012b; Nelson et al., 2010; Qin1402 Cell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc.et al., 2010). These studies have yielded a basic understanding
of the ‘‘healthy’’ human microbiome and have correlated devia-
tions from the healthy state to maladies such as obesity, dia-
betes, bacterial vaginosis, and Crohn’s disease (Gajer et al.,
2012; Gevers et al., 2012, 2014; Ravel et al., 2011; Turnbaugh
et al., 2009). Several recent studies have begun to examine the
human microbiome from a functional point of view, where direct
molecular interactions between host and microbe are revealed
(An et al., 2014; Hsiao et al., 2013; Mazmanian et al., 2005; Maz-
manian et al., 2008; Nougayre`de et al., 2006; Wieland Brown
et al., 2013; Wyatt et al., 2010).
Diffusible and cell-associated small molecules often mediate
host-microbe interactions in complex environments. Examples
of small-molecule-mediated interactions have been revealed in
symbioses between bacteria and insects (Oh et al., 2009), ma-
rine invertebrates (Kwan et al., 2012), nematodes (McInerney
et al., 1991), and plants (Long, 2001). In addition, several studies
have explored the role of small molecules in interactions
between microbiota and the mammalian host. For example,
Staphylococcus aureus pyrazinones were shown to be inducers
of bacterial virulence (Wyatt et al., 2010), the Escherichia coli
metabolite colibactin was found to contribute to colon cancer
(Nougayre`de et al., 2006), and polysaccharide A from Bacter-
oides fragilis has been shown to suppress the gut mucosal
immune response (Mazmanian et al., 2005, 2008). Recently,
we and others showed that Bacteroides fragilis produces the ca-
nonical CD1d ligand a-galactosylceramide, revealing a specific
mechanism by which the gut microbiota are capable of modu-
lating host natural killer T cell function (An et al., 2014; Wieland
Brown et al., 2013). Another recent study correlated the preva-
lence of hepatic cancer in mice to deoxycholic acid, a secondary
bile acid produced by certain members of the gut microbiota
(Yoshimoto et al., 2013). A recent metatranscriptomic study
showed the expression of genes matching the clusters of orthol-
ogous groups (COG) category ‘‘secondary metabolites biosyn-
thesis, transport, and catabolism,’’ which is consistent with the
possibility of small-molecule production but could also indicate
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Figure 1. Overview of BGCs in the Human
Microbiome
(A) Computational and experimental workflow for
the identification of BGCs from human-associ-
ated bacteria.
(B) A bar graph showing the top 30 families by
average BGC abundance from the human micro-
biome and the average number and type of BGCs
discovered in isolates of each genus using the
workflow in (A). See also Figure S1 andData S1 for
the full data set of predicted BGCs.the expression of catabolic and/or transport genes unrelated to
biosynthesis (Leimena et al., 2013). These examples raise the
question of whether there exists a much larger set of bacterially
produced molecules that mediate microbiota-host interactions.
Due to the complexity of the human microbiome and its vast
coding potential, a more systematic approach is needed to
explore small-molecule-mediated interactions between humans
and their microbiota.
In this study, we explored the biosynthetic capacity of the hu-
manmicrobiome by performing the first systematic identification
and analysis of its biosynthetic gene clusters. Unlike previous
approaches that have focused on one compound or bacterial
strain at a time, our approach allows the global analysis of
biosynthetic gene clusters (BGCs) that encode small molecules
in thousands of isolates of the human microbiota. By measuring
the representation of these BGCs in human metagenomic sam-
ples, we can assess the small-molecule coding capacity of a
community, generating powerful hypotheses about which mole-
cules might mediate microbe-host and microbe-microbe inter-
actions in a particular community and how their prevalence
differs among individuals. To illustrate the utility of this approach,
we used a combination of chemistry, genetics, metagenomics,
and metatranscriptomics to study a family of gene clusters that
is widely distributed in the human microbiome, including the
characterization of its small-molecule product and the analysis
of its prevalence among body sites and individuals.
RESULTS
A Systematic Approach Identifies 3,118 Biosynthetic
Gene Clusters that Are Present in Human Metagenomic
Samples
The identification of biosynthetic gene clusters in bacterial
genome sequences has become a powerful tool for natural prod-
uct discovery. We began by using an algorithm we recently
developed, ClusterFinder, to systematically analyze 2,430 refer-
ence genomes of the human microbiota from a range of bodyCell 158, 1402–1414, Sepsites (Cimermancic et al., 2014). Cluster-
Finder detected >14,000 biosynthetic
gene clusters (average of 6 gene clusters
per genome) for a broad range of small-
molecule classes, including saccha-
rides, nonribosomal peptides (NRPs),
polyketides (PKs), ribosomally encoded
and posttranslationaly modified peptides(RiPPs), NRPs-independent siderophores, and hybrids thereof
(Figure 1 and Figure S1 available online).
Reasoning that the small-molecule products of BGCs that
are widely distributed in the human population are most likely
to mediate conserved microbe-host and microbe-microbe inter-
actions, our next goal was to identify the subset of BGCs that is
commonly found in healthy individuals. To achieve this goal, we
examined the representation of these gene clusters in shotgun
metagenomic sequencing data generated by the Human Micro-
biome Project (HMP, 752 samples collected from five main body
sites of healthy subjects) (Human Microbiome Project Con-
sortium, 2012b). Briefly, we used mblastx (Davis et al., 2013) to
detect metagenomic reads that match the >14,000 predicted
BGCs (see Experimental Procedures for a more detailed
description of how gene clusters were quantified in metage-
nomic samples). Using this method, we calculated that a subset
of 3,118 biosynthetic gene clusters (22%) are present in the
microbiomes of healthy individuals; all subsequent analyses
focused on this subset (Figures 1 and S1 and Data S1).
An Overview of BGC Types and Distribution in the
Human Microbiome
The identification of >3,000 biosynthetic gene clusters in the hu-
man microbiome was remarkable, given that almost nothing
is known about their small-molecule products or biological activ-
ities. We next examined the distribution and abundance of each
of these BGCs in the 752 HMP samples.
The gut and oral cavity are by far the richest in BGCs, reflecting
their increased microbial abundance relative to the other body
sites (see also Figure S2A, see Experimental Procedures) (Hu-
man Microbiome Project Consortium, 2012b). A typical gut har-
bors 599 clusters, whereas a typical oral cavity harbors 1,061
clusters; notably, the SD of each of these values is large (152
and 143, respectively), pointing to a far greater degree of gene
cluster diversity in some individuals than others. Typical skin,
airway, and urogenital tract samples harbor many fewer BGCs
on average (101, 31, and 41, respectively, see also Table S1).tember 11, 2014 ª2014 Elsevier Inc. 1403
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The smaller number of BGCs in the skin, airway, and urogenital
tract communities could be a result of the lower microbial diver-
sity in these communities in comparison to the oral and gut
microbiota (Human Microbiome Project Consortium, 2012b).
In addition, fewer samples were sequenced from skin, airways,
and urogenital tract communities (27, 65, and 94 samples,
respectively) than from oral and gut communities (415 and 147,
respectively), possibly affecting the total number of BGCs that
were found to be present in these body sites.
The gene cluster classes in the human microbiota differ in
important ways from those in non-human-associated bacteria
(see also Figure S2B). Even in light of the predominance of sac-
charides among environmental bacteria (Cimermancic et al.,
2014), saccharides are significantly enriched in the microbiota
(see also Figure S2B), making them by far the most abundant
BGC class in the gut and oral cavity (average of 443 and 662
saccharide clusters per sample, respectively). RiPPs, which
are modestly enriched, are broadly distributed in every body
site. Although nonribosomal peptide synthetase (NRPS) and pol-
yketide synthase (PKS) gene clusters are significantly depleted
in the microbiota, they are still present at moderate levels
(average of 57 PKS and 19 NRPS clusters in a gut sample and
129 PKS and 46 NRPS clusters in an oral cavity sample; see
also Table S1), and notable exemplars are widely distributed in
the healthy human population (see below). Most of the BGCs
from nonhuman environmental isolates are harbored by mem-
bers of the abundant genera Streptomyces, Bacillus, Pseudo-
monas, Burkholderia, and Myxococcus (Cimermancic et al.,
2014); in contrast, most human-associated BGCs are harbored
by members of the abundant human-associated genera Bacter-
oides, Parabacteroides, Corynebacterium, Rothia, and Rumino-
coccus (up to seven BGCs per genome), pointing to undermined
taxa that should be rich BGC sources for experimental mining
efforts (Figure 1 and see also Figure S1). Many of these genomes
harbor large BGCs despite being only 2 to 3 Mb, suggesting
an important ecological role for their small-molecule products.
Some common genera of the human microbiota, including
Escherichia, Lactobacillus, Haemophilus, and Enterococcus,
harbor fewer than two BGCs per genome. Taken together, these
findings indicate that the human microbiome harbors a rich and
diverse array of BGCs that is mostly distinct in source and
composition from that of nonhuman isolates.
The best-studied gene clusters are not widely distributed
among healthy individuals. With the exception of the pyrazinone
BGC from S. aureus (found in >9% of the airways samples), two
of the most thoroughly studied BGCs from human-associated
bacteria are found in <5% of the samples from their body site
of origin (colibactin from E. coli and polysaccharide A from
Bacteroides fragilis (Mazmanian et al., 2005; Nougayre`de et al.,Figure 2. A Selected Subset of BGCs from the Human Microbiota
(A) 25 selected BGCs from the humanmicrobiota, spanning each of the body sites
terpenes, NI siderophores, and saccharides), and prevalent bacterial phyla (Acti
gene cluster indicates its source organism, body site of origin, and the percentag
these BGCs are present in more than 10% of the samples from their body site o
(B) Heat map showing the representation of BGCs from (A) in a subset of 60 selecte
heatmap represents an abundance score ranging from 10 (blue) to 1,000 (red) (key
abundance scores and see also Figure S2 and Table S1).
C2006; Wyatt et al., 2010). In contrast, nearly all of the BGCs
from our data set that are widely distributed in healthy humans
(present in >10% of the samples from the body site of origin)
have never been studied or even described; a selected subset
of these clusters is shown in Figure 2 (bgc01–bgc25). These re-
sults illustrate how little is known about the small-molecule prod-
ucts of the most common BGCs in human-associated niches.
Intriguingly, a smaller subset of 519 clusters is present
in >50% of the gut samples; similar ‘‘common’’ BGC subsets
are present in the oral cavity (582 clusters), skin (65 clusters),
urogenital tract (16 clusters), and airways (11 clusters) (see
also Table S1). In addition, several widely distributed families
of closely related BGCs were revealed by our analysis. Among
these BGC families, four examples stood out because of their
predominance in a body site, resemblance to a known BGC, or
cosmopolitan distribution: a family of NRPS BGCs from the
gut, a pair of PKS BGCs from the oral cavity, Bacteroidetes
saccharides, and RiPPs.
A Large Family of Nonribosomal Peptide BGCs Is Widely
Distributed in the Gut Community
The first BGC family we identified is a set of NRPS clusters that
are found exclusively in gut isolates (hereafter bgc26–bgc54).
Surprisingly, members of this family are harbored by species
of a wide variety of Gram-positive (Clostridium, Ruminococcus,
Eubacterium, Lachnospiraceae, Blautia) and Gram-
negative genera (Bacteroides and Desulfovibrio). In addition
to human gut isolates, this NRPS family is found in isolates
from the chicken gut (Bacteroides barnesiae DSM 18169) and
bovine rumen (Methanobrevibacter ruminantium M1) (Figure 3).
Remarkably, 137/149 (92%) of the HMP stool samples contained
at least one member of this family of NRPS clusters (see also
Figure S3), whereas none or very few of the airway (0/94), oral
(2/406), vaginal (2/65), and skin (1/27) metagenomic samples
harbored a member of this family. The wide distribution and
broad representation of this NRPS family suggests its impor-
tance for gut microbial inhabitants. Members of this BGC family
fall into two main groups: the first consists of three NRPS mod-
ules, whereas the second is composed of only two (Figure 3). The
predicted substrate of the penultimate adenylation domain is an
aliphatic amino acid (Leu, Ile, Val, or Ala), whereas the other ad-
enylation domains have predicted substrates that vary widely
among the clusters, suggesting that the small-molecule prod-
ucts of these BGCsmay be a family of closely related molecules.
A Family of Complex Polyketides from Oral
Actinobacteria Are Widely Distributed in the Oral Cavity
The most widely distributed multimodular PKS in the oral cavity
is a pair of closely related 80 kb clusters of the trans-AT type(gut, vagina, airways and skin, and oral cavity), BGC types (PKS, NRPS, RiPPs,
nobacteria, Bacteroidetes, Firmicutes, and Proteobacteria). The label of each
e of HMP samples harboring this cluster in its body site of origin. All but two of
f origin, indicating that they are widely distributed among healthy subjects.
d HMPmetagenomic samples from four body sites. The color of the cells in the
shown to the bottom, see Extended Experimental Procedures for calculation of
ell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc. 1405
(hereafter bgc54–bgc55). These clusters, which are found in two
different species of oral Actinobacteria (Propionibacterium pro-
pionicum F0230a and Actinomyces timonensis DSM 23838),
are strikingly similar in their domain architecture to a BGC from
the marine isolate Streptomyces sp. A7248 that encodes the
production of the homodimeric macrolide SIA7248 (Figure 4)
(Zou et al., 2013). Despite this similarity, the enzymes encoded
by the three clusters share only40% identity, and nomobile el-
ements were found in either of the human-associated clusters.
SIA7248 is chemically similar to the marinomycins, which are
known to have potent antibacterial and antitumor activity
(Kwon et al., 2006). Our computational analysis of PKS
architecture and AT domain selectivity predicts that the small-
molecule products of both PKS clusters will be nearly identical
to the marinomycins and SIA7248, except for an alternative
loading moiety activated by an acyl-CoA ligase domain that is
absent in the SIA7248 cluster. Notably, bgc54 is widely distrib-
uted in healthy subjects (34% of the HMP supragingival plaque
samples), indicating that a close relative of a complex marine
bacterial metabolite might be common in the oral cavity.
Bacteroidetes Saccharides Are Predominant and
Variable in the Gut
Saccharide BGCs are the most abundant family in each of the
five body sites and are particularly predominant in the gut
(74% of all BGCs in a typical HMP stool sample are saccharides;
see also Table S1). The phylum Bacteroidetes harbors the
largest number of saccharide BGCs (Cimermancic et al., 2014),
two of which have been structurally and functionally character-
ized (polysaccharide A and B; Baumann et al., 1992; Mazmanian
et al., 2005, 2008; Tzianabos et al., 1993). Two observations
were notable. First, among the most common saccharide
BGCs were capsular polysaccharide loci from B. vulgatus and
B. ovatus (see also Figure S4), which differ considerably from
the better-known examples in B. fragilis, suggesting that struc-
turally distinct capsular polysaccharides might be remarkably
common in the healthy human population. Second, ten HMP
stool samples that show similar taxonomic composition by
MetaPhlAn profiling (Segata et al., 2012) harbor largely distinct
sets of saccharide BGCs, with only a small number of BGCs
common among the samples (see also Figure S4). Thus, knowl-
edge about the taxonomic composition of gut communities from
16S rDNA analysis or metagenomic classification tools does not
reveal the inherent diversity of BGCs in these communities.
Ribosomally Synthesized, Posttranslationally Modified
Peptides Are among the Most Widely Distributed and
Variable BGCs Encoded by the Human Microbiota
BGCs encoding modified RiPPs are widely distributed among
the human microbiota. Three subclasses of RiPPs were particu-
larly notable: lantibiotics, which were numerous, variable, and
broadly distributed throughout the Firmicutes and Actinobacte-
ria from all of the major body sites; thiazole/oxazole-modified
microcins (TOMMs), which were prevalent in the oral cavity;
and thiopeptides. Although a small set of lantibiotics and
TOMMs have been isolated from members of the human micro-
biota (Chikindas et al., 1995; Gonzalez et al., 2010; Lee et al.,
2008), most are produced by pathogens or rare commensals.1406 Cell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc.Thiopeptides are highly modified RiPPs that have potent anti-
bacterial activity against Gram-positive species. A semisynthetic
member of this class, LFF571 (Novartis), is currently in phase II
clinical trials for treating Clostridium difficile infection (LaMarche
et al., 2012). Although a thiopeptide BGC was previously pre-
dicted by our group and others in the genome of the skin isolate
Propionibacterium acnes (Brzuszkiewicz et al., 2011; Wieland
Brown et al., 2009), no thiopeptide BGC or small-molecule prod-
uct from the human microbiome has ever been characterized
experimentally. Remarkably, in the analysis reported here, we
discovered thiopeptide-like BGCs in isolates from every human
body site (Lactobacillus gasseri, urogenital; Propionibacterium
acnes, skin; Streptococcus downei and S. sobrinus, oral;
and Enterococcus faecalis, gut). Additionally, we discovered a
thiopeptide gene cluster in the porcine gut isolate Lactobacillus
johnsonii PF01, indicating that thiopeptide BGCs are found in
the microbiota of animals other than humans (Figure 5A).
We next turned to the question of whether we could discover
additional thiopeptide gene clusters in metagenomic data
that were not present in any sequenced bacterial genome.
To address this question, we mined HMP metagenomic assem-
blies for the presence of additional thiopeptide gene clusters;
remarkably, we discovered eight additional thiopeptide BGCs
(7 complete, 1 partial) using this strategy, increasing the number
of thiopeptide BGCs identified here to 13 (bgc56-bgc68) (Fig-
ure 5A) (see Experimental Procedures). Of these, we found
one in human gut metagenomic samples (bgc61) and seven in
human oral metagenomic data sets (bgc58, bgc59, bgc62,
bgc64, bgc65, bgc67, and bgc68).
An analysis of the genes flanking these clusters suggests that
bgc61 resides in a prominent member of the human gut micro-
biome (Eubacterium rectale), whereas two of the oral metage-
nomic thiopeptide gene clusters are found in Actinomyces and
five others are harbored by Streptococcus (see also Table S2).
Transposases and phage integrases are unusually prevalent
among the thiopeptide BGCs (70%), and in at least one case
(bgc66), we could show bioinformatically and experimentally
that the cluster exists on a plasmid, suggesting a potential for
mobility (see below, and note that the thiopeptide BGC from
the porcine gut isolate Lactobacillus johnsonii PF01 [Lee et al.,
2011] also exists on a plasmid). Four of the 13 thiopeptide
BGCs are present in >20% of the HMP samples at one of the
body sites, and 155/406 HMP oral samples (38%) harbor at least
one thiopeptide BGC (Figure 5C and Table S2). For example,
bgc61 is present in 11% of gut samples and bgc65 is present
in 34% of oral samples, indicating that there exist widely distrib-
uted biosynthetic gene clusters in the healthy human population
that are not found in the reference genome database.
In order to gain more insight into the evolution of these human-
associated thiopeptide BGCs, we performed a detailed bio-
informatic analysis of their biosynthetic genes and precursor
peptides. Genomic and metagenomic thiopeptide BGCs fall
into six subfamilies in which members of each subfamily harbor
similar precursor peptides (Figures 5A and 5B). Notably, the
BGC precursor peptides and enzymes that posttranslationally
modify them cluster largely according to their body site of origin
rather than the phylogeny of their host (Figures 5A, 5B, and S5).
Moreover, the distribution of the oral thiopeptide clusters across
3 kb
NRPS
Transport
Regulatory
PPTase
Clostridium sp. CAG:470
Clostridium sp. CAG:452
Clostridium sp. CAG:798
Clostridium sp. CAG:780
Clostridium sp. CAG:389
Clostridium sp. CAG:269
Clostridium sp. CAG:356
Clostridium sp. CAG:567
C. saccharobutylicum DSM13864
Lachnospiraceae sp. 3_1_57FAA 
Clostridium sp. KLE 1755
Clostridium leptum CAG:27
Clostridium leptum DSM 753
Blautia producta ATCC 27340 
Clostridium sp. D5
C. scindens ATCC 35704
M. ruminantium M1
M. ruminantium M1
Desulfovibrio sp. 6_1_46AFAA
Clostridium sp. ASF502
Bacteroides sp. CAG:714
Ruminococcus sp. CAG:108
Ruminococcus bromii L2-63
Eubacterium limosum KIST612
S. wolfei subsp.wolfei
Eubacterium sp. 14-2
Clostridium sp. CAG:964
Clostridium sp. CAG:352
Firmicutes bacterium CAG:212
Firmicutes bacterium CAG:95
Ruminococcus sp. JC304
R. sp. 5_1_39BFAA
Ruminococcus sp. CAG:9
A. woodii DSM 1030
100
100
100
100
100
100
99
89
100
100
100
51
100
100
99
75
100
76
90
100
99
100
100
61
75
99
100
99
100
C
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T R
C
A
TC
A
T
A
T R
A
C
A
TC
A
TC
A
T
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
A
T
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
A
T
C
A
TC
A
T R
A
T
C
A
TC
A
T R
A
T
C
A
TC
A
T R
A
T
C
A
TC
A
T R
A
T
C
A
TC
A
T
A
T R
A
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T
A
T R
C
A
TC
A
T R
A
T
bgc26 
bgc27 
bgc28 
bgc29 
bgc30 
bgc31 
bgc32 
bgc33 
bgc34 
bgc35 
bgc36 
bgc37 
bgc38 
bgc39 
bgc40 
bgc41 
bgc42 
bgc43 
bgc44 
bgc45 
bgc46 
bgc47 
bgc48 
bgc49 
bgc50 
bgc51 
bgc52 
bgc53
Figure 3. An Abundant Family of NRPS BGCs Is Found Exclusively in Gut Isolates and Stool Metagenomes
Left, a phylogenetic tree (Maximum Parsimony, MEGA5) based on the main NRPS gene of 28 clusters from human bacterial gut isolates, two from bovine rumen
archaeal isolates, and four from environmental isolates (see Experimental Procedures). The numbers next to the branches represent the percentage of replicate
trees in which this topology was reached in a bootstrap test of 1,000 replicates. Middle, schematic of each BGC (see also Figure S3 for a full heat map showing
the prevalence and abundance of each member of this NRPS family in HMP stool samples). Right, domain organization of the NRPS genes of each cluster
(A, adenylation domain; C, condensation domain; T, thiolation domain; R, terminal reductase domain).
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Figure 4. A Family of Complex PKS BGCs Is Prevalent in the Human Oral Cavity
(A) Related PKS BGCs in human oral actinobacteria P. propionicum F0230a and A. timonensis DSM 23838 and the marine actinobacterium Streptomyces sp.
A7248. The label of each BGC indicates its source organism.
(B) Domain organization of the three BGCs shown in (A) (AT, acyltransferase domain; KS, ketosynthase domain; MT, methyltransferase domain; Ox, oxidation
domain; ECH, enoyl-CoA hydratase domain; DH, dehydratase domain; KR, ketoreductase domain; ACL, acyl-CoA ligase domain; T, thiolation domain, HCS,
HMG-CoA synthase domain; FKB, FkbH-like protein. Note that the domain architecture is remarkably conserved among the three pathways, despite low amino
acid sequence identity (40%).
(C) Structures of SIA7248, the product of the Streptomyces sp. A7248 BGC shown in (A), and the related molecule marinomycin A.the sample set indicates that most of the samples harbor only
one thiopeptide BGC (Figure 5C). Taken together, these results
are consistent with the possibility that thiopeptide gene clusters
are mobile and that they undergo horizontal transfer among the
microbiota within a body site (Smillie et al., 2011).
Discovery and Characterization of a Thiopeptide from
the Human Microbiome
We next set out to purify and solve the structure of a thiopeptide
from the human microbiome. Of the 13 thiopeptide BGCs
described here, three resembled BGCs for known thiopeptides
(bgc56 is homologous to the berninamycin BGC from Strepto-
myces bernensis, and one of its two putative precursor peptides
is identical to that of berninamycin [Malcolmson et al., 2013]).
Likewise, the genetic organization and precursor peptide
sequences of bgc68 and bgc66 are similar to those of the TP-
1161 (Nocardiopsis sp. TFS65-07) and thiocillin (Bacillus cereus
ATCC 14579) BGCs, respectively (Engelhardt et al., 2010; Liao
et al., 2009; Wieland Brown et al., 2009). Because there is
more precedent for the genetic manipulation of Lactobacillus1408 Cell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc.than Propionibacterium and bgc68 does not exist in any of the
reference strains, we selected bgc66 for chemical and biological
characterization.
The reference genome in which bgc66 resides is a vaginal
isolate of Lactobacillus gasseri from a subject in Texas
(L.gasseriJV-V03,HMPDACC);L.gasseri is oneof the fourLacto-
bacillus species that commonly dominate the vaginal community
(Ravel et al., 2011). In order to determine whether the small-
molecule product of bgc66 is produced under conditions of labo-
ratory culture, we constructed an insertional mutant of the gene
harboring a YcaO domain (locus tag: HMPREF0514_11730) by
single crossover mutagenesis (see Experimental Procedures).
By comparing the HPLC and LC-MS profiles of organic extracts
of thewild-type andbgc66::HMPREF0514_11730mutant strains,
we identified a single peak that is present in the wild-type but
missing in the insertional mutant (Figure 6A). This peak had an
absorption spectrum consistent with a compound that harbors
a trithiazoylpyridine core (Figure 6A and see also Figure S6).
High-resolution mass spectrometry enabled us to calculate
the empirical formula C51H45N13O10S7 (observed [M+H]
+ at m/z
1224.15184, calculated [M+H]+ 1224.15354, Dppm = 1.3). This
mass and empirical formula deviated from the computationally
predicted mass and empirical formula for the bgc66 product
(1058.0667 and C42H34N12O8S7, respectively), suggesting that
the bgc66 product harbored at least one unknown posttransla-
tional modification.
To obtain multimilligram quantities of the bgc66 product for
structural characterization, we performed a 50 L cultivation of
L. gasseri JV-V03. Our initial attempts to perform NMR experi-
ments on the isolated product failed due to its low solubility in
NMR solvents and apparent instability. Hypothesizing that the
bgc66 product harbored a free carboxylic acid that was partly
responsible for its insolubility and instability, we treated the prod-
uct extracted from a second 60 L cultivation with TMS-diazome-
thane to convert any free carboxylic acids to methyl esters. The
resulting product had a mass consistent with the addition of a
single methyl group and exhibited greatly improved solubility
and stability. After extensive purification by HPLC, the purified
product (0.5 mg) was characterized using a series of 1D and 2D
NMR experiments, high-resolution tandem mass spectrometry
(MS/MS and MSn), and isotope labeling experiments. Collec-
tively, these data enabled us to determine the structure of the
bgc66 product, to which we assign the name lactocillin (see
Experimental Procedures, Figures 6B and S6, and Data S2).
Lactocillin harbors a canonical 26-membered thiopeptide scaf-
fold, with a trithiazolylpyridine core and a macrocycle with four
cysteine-derived heterocycles and a single dehydrobutyrine res-
idue. Three structural features set it apart from thiocillin. (1) The
presence of an indolyl-S-cysteine residue at position 8, a feature
that is structurally and regiochemically reminiscent of the 3-meth-
ylindolyl andquinaldic acidmoieties of nosiheptide and thiostrep-
ton, respectively (Just-Baringo et al., 2014; Kelly et al., 2009; Liao
et al., 2009; Yu et al., 2009). Interestingly, the enzymes predicted
to install the indolyl-S-cysteine in lactocillin (lclI, a thiolation
domain, lclJ, an adenylation domain, and lclK, an alpha-beta
hydrolase) are unrelated to any genes in the nosiheptide or thio-
strepton BGCs, indicating that it may have arisen by convergent
evolution. Lactocillin also (2) harbors a free carboxylic acid at
the C terminus, a rare feature among thiopeptides (Just-Baringo
et al., 2014) and (3) lacks any oxygen-requiring posttranslational
modifications, reflecting the anaerobic conditions under which
L. gasseri thrives in the vaginal community (Figure 6B).
Next,we set out todeterminewhether lactocillin has a spectrum
of activity similar to other thiopeptides, which are potent antibi-
otics against Gram-positive, but not Gram-negative, bacteria.
To answer this question, we tested purified lactocillin against
commonlyobservedpathogensandcommensals fromthe vaginal
community. Lactocillin was active against Staphylococus aureus,
Enterococcus faecalis, Gardnerella vaginalis, and Corynebacte-
rium aurimucosum, but not Escherichia coli, an activity spectrum
similar to that of other thiopeptides and suggestive of a potential
role in protecting the vaginal microbiota against pathogen inva-
sion. Interestingly, lactocillinwas inactive against the vaginal com-
mensals Lactobacillus jensenii JV-V16, Lactobacillus crispatus
JV-V01, and L. gasseri SV-16A-US (a different strain from the lac-
tocillin producer) at 425 nM, raising the possibility that the vaginal
microbiota have evolved resistance against a compound they
commonly encounter (Table 1 and see Experimental Procedures).CMetatranscriptomic Data Analysis Reveals that the lcl
Cluster Is Expressed in Humans
We next examined the distribution pattern of the lcl gene cluster
in the human microbiota. In contrast to other human-associated
thiopeptide BGCs (Figures 5A and 5C), the lcl gene cluster ap-
pears to have a limited distribution in genomic and metage-
nomic data sets: L. gasseri JV-V03 is the only one of the ten
sequenced L. gasseri genomes that harbors the cluster (see
Extended Experimental Procedures), and none of the six vaginal
metagenomic samples in which L. gasseri is the dominant strain
contain reads that match the lcl cluster. However, building on
the finding that lcl resides on a plasmid (Figure 6C) and that
some BGCs are present in more than one body site (see also
Figure S2), we broadened our search to publicly available meta-
transcriptomic data sets from the oral cavity (see Experimental
Procedures). To our surprise, we found that two thiopeptide
gene clusters—lcl and bgc65—were covered by oral metatran-
scriptomic reads in multiple samples (in total, reads matching lcl
and bgc65 were found in 3/38 and 11/38 of the supragingival
plaque metatranscriptomic samples, respectively) (see Experi-
mental Procedures, Figure 6D and see also Figure S7). In
addition, the rest of genes on the plasmid in which the lcl cluster
resides were also present in oral metatranscriptomic samples,
further emphasizing its mobility (see also Figure S7). These
results show that thiopeptide gene clusters are actively tran-
scribed in human samples, suggesting a potential role in medi-
ating microbe-microbe interactions in the communities in which
they are expressed.
DISCUSSION
Here, we systematically identify BGCs in the genomes of human
isolates, examine their representation in metagenomic and
metatranscriptomic samples, identify widely distributed BGC
families, and characterize the structure and activity of their
small-molecule products. Our approach introduces a method
for identifying and prioritizing BGCs for experimental character-
ization and can easily be generalized to other BGC families. The
resulting database of BGCs that were detected in human sam-
ples (see also Data S1) will serve as a resource for future studies
that aim to discover small-molecule-mediated interactions in the
human microbiota.
Our approach has three important limitations. First, we rely
on sequenced isolates of the human microbiota to predict
the initial set of BGCs that we later use to recruit reads from
whole-genome shotgun metagenomic samples. Although the
2,400 bacterial genomes that we analyze here span all of the
human-associated bacterial phyla and represent each major
body site, they are biased toward gut and oral residents and
easily cultivated species, for example.
Second, in examining the representation of BGCs in human
metagenomic samples, we relied on the HMP whole-genome
shotgun metagenomic data sets, which were sampled from
fewer body sites and subsites than the larger 16S data set. Fewer
samples were sequenced from skin than other body sites
(27 versus at least 60 for all other body sites), and these samples
were all obtained from one skin subsite (retroauricular crease).
We anticipate that the number of skin-associated BGCs willell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc. 1409
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Figure 6. Characterization of an Antibiotic, Lactocillin, from a Human Vaginal Isolate
(A) HPLC analysis of organic extracts of cell pellets from wild-type (red) and lclD insertional mutant (blue) strains of L. gasseri JV-V03, monitored at 350 nm. An
asterisk indicates the HPLC peak corresponding to lactocillin.
(B) Planar structure of lactocillin (see Experimental Procedures and see also Figure S6 and Data S2 for details about its purification and structural elucidation), the
Bacillus cereus antibiotic thiocillin, and the clinical candidate LFF571 (Phase II, Novartis). Note the structural similarities among the three thiopeptides.
(C) Plasmid harboring the lactocillin BGC (see Experimental Procedures for details of the experimental closure of the circular plasmid). The lactocillin gene cluster
(red) occupies30% of the plasmid; other elements on the plasmid include plasmid replication and maintenance genes (blue), transporters (black), transcription
regulators (brown), and transposases and phage integrases (white).
(D) Raw oral metatranscriptomic readswere recruited to the lcl cluster using blastn and aligned usingGeneious. Each black bar represents one read. Note that the
precursor peptide lclB is among the most deeply covered genes in the lcl cluster, as anticipated for a RiPP pathway (see Experimental Procedures and see also
Figure S7 for metatranscriptomic analysis of the whole lcl plasmid and of bgc65).rise as the number and diversity of whole-genome shotgun
metagenomic data sets increases.
Third, we show that metatranscriptomic reads matching the
lcl cluster exist in RNA-seq data from the human oral cavity, sug-
gesting that the lcl cluster is expressed in humans. To prove
conclusively that lactocillin is produced in humans, it would
need to be directly detected in human vaginal or oral samples
using sensitive analytical techniques. The activity of lactocillin
in its native context will need to be further explored in coloniza-
tion experiments in which a lactocillin producer is compared to
an isogenic strain deficient in lactocillin production.Figure 5. Thiopeptide BGCs Are Widespread in Isolates and Metageno
(A) Five thiopeptide BGCs from human isolates, eight thiopeptide BGCs from hum
label of each BGC indicates its body site of origin.
(B) Precursor peptides corresponding to the thiopeptide BGCs shown in (A). Note t
The structural portion of the precursor peptide is shown in red (see also Figure S
(C) A heat map showing the representation and abundance of six oral thiopeptid
tification of all thiopeptide BGCs in all HMP samples). Note that, although each B
harbor only one thiopeptide BGC.
CLandmark studies of gene clusters encoding catabolic path-
ways from the microbiota have shown the power of connecting
genes to microbiome-related functions. Sonnenburg et al.
(2010) and Larsbrink et al. (2014) have dissected the function
of gene clusters from Bacteroides that catabolize fructans
and xyloglucans, respectively. Both studies lend important
insights into the role of specialized catabolic modules in
competition for nutrient niches in the gut community, and
they demonstrate that a mechanistic understanding of gene
cluster function yields predictive power into how members of
the gut community will respond to a change in diet. The currentmes of All Main Human Body Sites
an metagenomes, and one thiopeptide BGC from a pig isolate are shown. The
hat the precursor peptides fall into six subgroups of nearly identical sequences.
5 for a phylogenetic analysis of thiopeptide BGCs).
e BGCs in HMP metagenomic oral samples (see also Table S2 for the quan-
GC shown in the heat map is well represented in the oral cavity, most samples
ell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc. 1411
Table 1. Minimum Inhibitory Concentration of Lactocillin against
Vaginal and Oral Pathogens and Commensals
Strain Phylum Description
Lactocillin
MIC (nM)
Staphylococcus
aureus
Firmicutes pathogen 42a
Escherichia coli Proteobacteria commensal NAb
Enterococcus
faecalis
Firmicutes pathogen 425
Lactobacillus
jensenii
Firmicutes vaginal
commensal
NAb
Lactobacillus
gasseric
Firmicutes vaginal
commensal
NAb
Lactobacillus
crispatus
Firmicutes vaginal
commensal
NAb
Corynebacterium
aurimucosum
Actinobacteria vaginal
pathogen
42a
Finegoldia magna Firmicutes vaginal pathogen NAb
Gardnerella vaginalis Actinobacteria vaginal pathogen 212
Streptococcus
sanguinis
Firmicutes oral commensal 212
Streptococcus
sobrinus
Firmicutes oral commensal/
pathogen
85
Streptococcus
mutans
Firmicutes oral commensal/
pathogen
425
See Experimental Procedures for details. Streptococcus sanguinis and
Gardnerella vaginalis were partially inhibited at 80 nM lactocillin but not
completely until the next concentration tested (212 nM). Streptococcus
mutans was partially inhibited at 212 nM but not completely until the
next concentration tested (425 nM).
aLowest concentration tested was 42 nM.
bHighest concentration tested was 425 nM.
cNote that the strain of L. gasseri tested was SV-16A-US, which is a
different strain from the lactocillin producer (JV-V03).state of knowledge of how BGCs in the human microbiota func-
tion is comparatively less well developed but holds great prom-
ise in yielding similar insights into microbe-host and microbe-
microbe interactions.
The small-molecule products of BGCs are widely used in
the clinic, and they constitute much of the chemical language
of interspecies interactions. Our data highlight the fact that there
exist hundreds of widely distributed BGCs of unknown function
in the human microbiome, and they provide a template for future
experimental efforts to discover biologically active small mole-
cules from the microbiota (see also Data S1 for a full data set
of human-associated BGCs). These molecules represent a
promising starting point for studying microbe-host interactions
at the level of molecular mechanism and potentially a rich source
of therapeutics.
EXPERIMENTAL PROCEDURES
Computational Analysis of BGCs from the Human Microbiome
Genome sequences of 2,430 bacterial strains isolated from humans were
obtained from JGI-IMG, and BGCswere predicted usingClusterFinder (Cimer-
mancic et al., 2014). The initial set of 44,000 putative BGCs was then analyzed1412 Cell 158, 1402–1414, September 11, 2014 ª2014 Elsevier Inc.by antiSMASH (Medema et al., 2011), which classified a subset of 14,000
BGCs into a known category. A database containing the amino acid sequence
of each gene in these 14,000 BGCs was constructed and queried against the
processed (post-QC) reads of 752 HMP metagenomic samples using mblastx
(Davis et al., 2013). Abundance scores of genes and gene clusters were calcu-
lated, and 3,118 BGCs were found to be present in at least one metagenomic
sample (see also Extended Experimental Procedures and Data S3 for details
about abundance score calculations, thresholds, and additional computa-
tional analyses).
Identification of Thiopeptide BGCs from HMP Metagenomic Data
A database containing the amino acid sequence of 24 homologs of TclM
(the enzyme responsible for pyridine ring formation in thiocillin) was con-
structed. This data set was then used as a query for tblastn searches
against metagenomic assemblies of the 752 HMP samples. Contigs that
generated hits to multiple thiopeptide genes were analyzed using
antiSMASH, and results were verified manually. A thiopeptide BGC was
called only when genes for all the essential posttranslational modifications
were identified in addition to the precursor peptide (see also Extended
Experimental Procedures).
Generation of an Insertional Mutant in L. gasseri JV-V03 and
Verification of Lactocillin Production
L. gasseri JV-V03 was cultivated in an anaerobic chamber (80% N2, 10%CO2,
and 10% H2) in MRS broth (BD) at 37
C. A 1,000 bp fragment of lclD was PCR
amplified and cloned into pKM082, a suicide vector harboring an erythro-
mycin resistance gene. L. gasseri JV-V03 was transformed with this vector
by electroporation, and transformants were selected on erythromycin and
verified using PCR (see also Extended Experimental Procedures and Table
S3). Cell pellets from the wild-type strain and insertional mutants were
grown in 1 L MRS broth, extracted with methanol, and analyzed using HPLC
and LC-MS monitoring at 350 and 220 nm.
Large-Scale Production and Derivatization of Lactocillin
A 60 L culture of L. gasseri JV-V03 was grown for 2 days at 37C. Cell
pellets were harvested and extracted with 3 L methanol. Organic extracts
were dried using rotary evaporation and fractionated on a C18 Sep
Pak column using a step gradient of 20%, 40%, 60%, 80%, and 100%
methanol in water. Lactocillin eluted in the 80% and 100% fractions, as
determined by LC-MS. Semipurified lactocillin from the 80% fraction was
methylated using TMS-diazomethane, and the methylated lactocillin prod-
uct was purified by preparative HPLC (see also Extended Experimental
Procedures).
Structural Elucidation of Lactocillin Methyl Ester
The structure of purified lactocillin methyl ester was solved using a combina-
tion of MS experiments (HRMS, HRMS/MS, and HRMSn) and 1D and 2D
NMR spectroscopy experiments (1D 1HNMR, gCOSY, HSQC, HMBC, and
ROESY). In addition, heavy isotope feeding experiments were performed to
confirm the identity of the indolyl acyl group in the structure (see also Extended
Experimental Procedures).
Purification and MIC Determination of Lactocillin
Lactocillin was purified by preparative HPLC from the 100% Sep Pak fraction
and quantified using HPLC. The minimal inhibitory concentration of purified
lactocillin against a suite of commensal and pathogenic vaginal and oral iso-
lates was tested using a range of concentrations from 42 to 425 nM. A
vehicle-alone control was used in each experiment (see also Extended Exper-
imental Procedures).
Metatranscriptomic Analysis of Thiopeptide BGCs
A database containing the nucleotide sequences of all human-associated
thiopeptide BGCs was generated. Raw Illumina reads from 38 oral meta-
transcriptomic samples were compared to this database using blastn,
and hits with expectation values < 1e10 were recruited to the clusters using
Geneious.
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